Suppr超能文献

药物过敏:爆发性反应、交叉反应和多种药物过敏。

Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity.

机构信息

Adverse Drug Reactions - Analysis and Consulting (ADR-AC) Division of Allergology, Clinic for Rheumatology and Clinical Immunology/Allergology Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

出版信息

J Dermatol. 2011 Mar;38(3):216-21. doi: 10.1111/j.1346-8138.2010.01142.x. Epub 2011 Feb 1.

Abstract

In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long-lasting antibiotic treatments. For the clinician, the question arises whether these symptoms are due to cross-reactivity, are due to a new sensitization or are a reflection of a multiple drug hypersensitivity syndrome. Based on the p-i concept (pharmacological interaction with immune receptors), we propose that the efficient stimulation of T cells by a drug is the sum of drug-T-cell receptor affinity and readiness of the T cell to react, and therefore not constant. It heavily depends on the state of underlying immune activation. Consequently, drug hypersensitivity diseases, which go along with massive immune stimulations and often high serum cytokine values, are themselves risk factors for further drug hypersensitivity. The immune stimulation during drug hypersensitivity may, similar to generalized virus infections, lower the threshold of T-cell reactivity to drugs and cause rapid appearance of drug hypersensitivity symptoms to the second drug. We call the second hypersensitivity reaction a "flare-up" reaction; this is clinically important, as in most cases the second drug may be tolerated again, if the cofactors are missing. Moreover, the second treatment is often too short to cause a relevant sensitization.

摘要

在药物过敏中,改变药物治疗并继续使用新药可能导致药物过敏症状再次出现。对于慢性感染需要持续和长期抗生素治疗的患者,这种情况并不罕见。对于临床医生来说,问题是这些症状是由于交叉反应、新的致敏还是多种药物过敏综合征的反映。基于 p-i 概念(与免疫受体的药物相互作用),我们提出药物对 T 细胞的有效刺激是药物-T 细胞受体亲和力和 T 细胞反应准备程度的总和,因此不是恒定的。它严重依赖于潜在免疫激活的状态。因此,伴随着大量免疫刺激和常伴有高血清细胞因子值的药物过敏疾病本身就是进一步发生药物过敏的风险因素。药物过敏期间的免疫刺激类似于全身性病毒感染,可能会降低 T 细胞对药物反应的阈值,并导致对第二种药物迅速出现药物过敏症状。我们将第二次过敏反应称为“爆发”反应;这在临床上很重要,因为在大多数情况下,如果没有共同因素,第二种药物可能再次耐受,如果第二次治疗时间太短,通常不会引起相关的致敏。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验